Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis
1990; Elsevier BV; Volume: 335; Issue: 8697 Linguagem: Inglês
10.1016/0140-6736(90)92630-z
ISSN1474-547X
AutoresPeter Tugwell, Claire Bombardier, Peter Tugwell, Michael Gent, Kathryn Bennett, R.S. Roberts, D Ludwin, W. Bensen, Simon Carette, Andrew Chalmers, Alice Klinkhoff, John M. Esdaile, G Kraag,
Tópico(s)Peripheral Neuropathies and Disorders
Resumo144 patients with severe rheumatoid arthritis from six centres were randomised to receive oral cyclosporin or placebo for 6 months. The initial daily dose of cyclosporin was 2·5 mg/kg, which was increased cautiously with monitoring of serum cyclosporin levels and creatinine; the mean stabilisation dose was 3·8 mg/kg. There were significant improvements in the cyclosporin-treated patients compared with the controls in the major outcomes of reduction of active joints (23% improvement), pain (24%), and functional status (16%); global improvement was 27%. In the cyclosporin group serum creatinine increased by a mean of 15·6 μmol/l and mean arterial blood pressure by 6·27 mm Hg; these increases were controlled in all but 2 patients by dose adjustment without withdrawal from the study.
Referência(s)